23 November 2017
News and Views
Links and Services
The latest issue of the Alimentary Pharmacology & Therapeutics finds enhanced adherence to HCV therapy with higher dose ribavirin formulation.
Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. <
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors